Two July Deadlines Define Bayer’s Next Move After a Landmark Legal Win
27.06.2026 - 20:02:20 | boerse-global.de
The Supreme Court may have handed Bayer a historic victory, but the stock’s next leg hinges on two sharply contrasting events packed into the second half of 2026. On 9 July, a Missouri judge will decide whether to approve a $7.25bn settlement that could slash the legal overhang further. By year-end, the FDA is expected to rule on Asundexian, the drug candidate Bayer needs to fill the revenue hole left by its fading blockbuster Xarelto. Either milestone could either cement the rally — or trigger a reversal.
Wall Street had already priced in some optimism after the Supreme Court ruling on 25 June. The justices voted 7–2 to bar state-level failure-to-warn claims against glyphosate products, siding with the EPA’s determination that the herbicide does not cause cancer. The decision — formally handed down in Durnell v. Monsanto — invokes the Federal Insecticide, Fungicide, and Rodenticide Act and, in Bayer’s view, “provides scientific clarity and regulatory predictability.” The group now expects to have thousands of pending and future Roundup lawsuits dismissed.
The market reaction was electric. Bayer shares surged as much as 20% on the day of the ruling, their biggest single-session leap since 2003. By Friday’s close the stock had settled at €46.61, up 23.27% for the week. That placed it well above the 200-day moving average of €36.59, though still roughly 7% below the 52-week high of €49.93. The relative strength index, however, hit 80.6 — deep into overbought territory — suggesting at least some of the euphoria may be vulnerable to profit-taking.
Yet the legal drama is far from over. Bayer remains committed to the proposed Missouri settlement, which covers a broad swath of unresolved claims. Judge Timothy Boyer will hold a final hearing on 9 July to decide whether to grant approval. Getting the green light would eliminate another major source of uncertainty and bring actual cash outflows into clearer focus. But the deal is not risk-free: Bayer can walk away if too many plaintiffs opt out, and a group of claimants has already appealed to the 8th U.S. Circuit Court of Appeals. Any hiccup could quickly shift attention back to the group’s balance sheet.
Should investors sell immediately? Or is it worth buying Bayer?
And that balance sheet remains stretched. Net debt stands at roughly €33bn. For the current year alone, CFO Wolfgang Nickl expects roughly €5bn in legal outflows — a figure underscored by the €2.32bn free-cash-flow drain recorded in the first quarter. While the Supreme Court victory curbs future state-level lawsuits, it does not erase the financial obligations already incurred or still being negotiated.
Meanwhile, Bayer’s pharmaceutical pipeline is carrying its own load of hope and hazard. Sales of the anticoagulant Xarelto tumbled by a third in 2025, to $2.6bn. The company’s best bet to fill the gap is Asundexian, a Factor XIa inhibitor that Bayer is positioning as a first-in-class option for secondary stroke prevention. In May 2026, the FDA accepted the filing for priority review, and regulators in China and Europe are also examining the application. A successful launch would give Bayer a huge addressable market — some ten million people in Europe alone living with stroke after-effects.
But the drug’s path has been rocky. Asundexian suffered a setback in 2023 in atrial fibrillation patients, forcing a repositioning of the clinical programme. A second failure in the current stroke trial would blow a hole in the company’s growth strategy. In the bull case, FDA approval before year-end, combined with the Missouri settlement being sealed in July, could lift the stock back toward its 52-week peak. The bear case: If the settlement collapses or Asundexian stumbles, the debt story returns to centre stage and the recent gains could evaporate quickly.
Bayer at a turning point? This analysis reveals what investors need to know now.
For now, Bayer’s rally looks as much about timing as about fundamentals. The twin catalysts of 9 July and the FDA decision are concrete, measurable and close enough to drive speculation. But with an RSI reading of 80.6, even a minor disappointment could trigger a sharp correction. The market is betting on a clean double — legal closure and pipeline success — but both must deliver on schedule.
Ad
Bayer Stock: New Analysis - 27 June
Fresh Bayer information released. What's the impact for investors? Our latest independent report examines recent figures and market trends.
